82% reduction in the risk of disease progression or death* vs. high-dose octreotide LAR** (HR [95% CI], 0.18 [0.11-0.29]; P<0.0001).1


The overall safety profile of LUTATHERA® is based on pooled data from clinical trials (NETTER-1 Phase III and Erasmus Phase I/II Dutch patients) and from compassionate use programs.1


Improvement in overall global health-related QoL up to week 84 with LUTATHERA® vs. high-dose octreotide LAR.**,†1

*NETTER-1 primary endpoint; cut-off date for primary analysis was 24th July 2015.1,2 **High-dose octreotide LAR 60mg is not the licensed dose. †Pre-specified analysis of NETTER-1.1
CI, confidence interval;G, grade; GEP-NET, gastroenteropancreatic neuroendocrine tumor; HR, hazard ratio; HRQoL, health-related quality of life; LAR, long-acting repeatable; QoL, quality of life.
References: 1. LUTATHERA® Summary of Product Characteristics. March 2022. 2. Strosberg J, El-Haddad G, Wolin E et al. Phase 3 trial of 177Lu-dotatate for midgut neuroendocrine tumors. N Engl J Med. 2017; 376(2): 125–135.

This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report upon local legislation or to use the pharmacovigilance link adacap.com/pharmacovigilance/.